{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:10:44Z","timestamp":1794330644135,"version":"4.9.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Clinical trials show that lumacaftor\/ivacaftor (LUM\/IVA) treatment has the potential to modify early cystic fibrosis (CF) disease progression in children as young as 2 years of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the long-term impact of LUM\/IVA treatment on CF disease progression in children aged 2\u20135 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 2 trial had two parts: part 1, a 48-week, randomized, double-blind, placebo-controlled study of LUM\/IVA in children aged 2\u20135 years (previously reported) was followed by a 48-week open-label treatment period in which all children received LUM\/IVA (part 2; reported here). Endpoints assessed in part 2 included absolute changes from baseline in chest magnetic resonance imaging (MRI) global score at Week 96; weight-for-age, stature-for-age, and body mass index (BMI)-for-age z-scores at Week 96; lung clearance index based on lung volume turnover required to reach 2.5% of starting N2 concentration (LCI2.5) through Week 96; chest MRI morphological score, chest MRI perfusion score, weight, stature, BMI, and microbiology cultures (oropharyngeal swabs) at Week 96; sweat chloride, amount of immunoreactive trypsinogen, fecal elastase-1 concentration, and fecal calprotectin through Week 96; and number of pulmonary exacerbations, time to first pulmonary exacerbation, and number of CF-related hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-nine children received one or more doses of LUM\/IVA in the open-label period (33 in the LUM\/IVA to LUM\/IVA group and 16 in the placebo to LUM\/IVA group), with a mean exposure of 47.1 (standard deviation [SD], 5.2) weeks. The mean absolute change in MRI global score (negative value indicates improvement) from baseline at Week 96 was \u22122.7 (SD, 7.0; 95% confidence interval [CI], \u22125.2 to \u22120.1) in the LUM\/IVA to LUM\/IVA group and \u22125.6 (SD, 6.9; 95% CI, \u22129.2 to \u22121.9) in the placebo to LUM\/IVA group. Improvements in LCI2.5, sweat chloride concentration, and markers of pancreatic function and intestinal inflammation were also observed in both groups. Growth parameters remained stable in both groups. The majority of children had adverse events considered mild (38.8%) or moderate (40.8%). Two (4.1%) children discontinued LUM\/IVA treatment because of adverse events (distal intestinal obstruction syndrome [n\u2009=\u20091] and alanine aminotransferase increase [n\u2009=\u20091]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings confirm the potential for early LUM\/IVA treatment to alter the trajectory of CF disease progression, including CF lung disease, in children as young as 2 years of age.<\/jats:p>\n                    <jats:p>Clinical trial registered with ClinicalTrials.gov (NCT03625466).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202402-201oc","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:57:30Z","timestamp":1724345850000},"page":"1550-1559","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":17,"title":["Long-Term Impact of Lumacaftor\/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2\u20135 Years of Age Homozygous for\n                    <i>F508del-CFTR<\/i>\n                    : A Phase 2, Open-Label Clinical Trial"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-8315","authenticated-orcid":false,"given":"Mirjam","family":"Stahl","sequence":"first","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine and"},{"name":"German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobst","family":"Roehmel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine and"},{"name":"German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Eichinger","sequence":"additional","affiliation":[{"name":"Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany"},{"name":"Department of Diagnostic and Interventional Radiology and"},{"name":"Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-8569","authenticated-orcid":false,"given":"Felix","family":"Doellinger","sequence":"additional","affiliation":[{"name":"Department of Radiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Justus Liebig University Giessen, Giessen, Germany"},{"name":"Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias V.","family":"Kopp","sequence":"additional","affiliation":[{"name":"Pediatric Respiratory Medicine, Department of Pediatrics, Inselspital, University of Bern, Bern, Switzerland"},{"name":"Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-1025","authenticated-orcid":false,"given":"Anna-Maria","family":"Dittrich","sequence":"additional","affiliation":[{"name":"Department for Pediatric Pulmonology, Allergology, and Neonatology, and"},{"name":"BREATH, German Center for Lung Research (DZL), Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Sommerburg","sequence":"additional","affiliation":[{"name":"Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany"},{"name":"Division of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center, Department of Pediatrics, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Ray","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Maniktala","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts; and"},{"name":"ICON plc, Global Strategic Solutions, Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu","family":"Xu","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Conner","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"Joshi","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Mascia","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-037X","authenticated-orcid":false,"given":"Mark O.","family":"Wielp\u00fctz","sequence":"additional","affiliation":[{"name":"Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany"},{"name":"Department of Diagnostic and Interventional Radiology and"},{"name":"Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine and"},{"name":"German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2026012203191180900_bib1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203191180900_bib2","author":"Cystic Fibrosis Foundation Patient Registry","year":"2022"},{"key":"2026012203191180900_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012203191180900_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-3476(95)70072-2","article-title":"Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis","volume":"127","author":"Couper","year":"1995","journal-title":"J Pediatr"},{"key":"2026012203191180900_bib5","first-page":"697","article-title":"Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and control infants","volume":"95","author":"Imrie","year":"1979","journal-title":"Am J Pathol"},{"key":"2026012203191180900_bib6","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O\u2019Sullivan","year":"2009","journal-title":"Lancet"},{"key":"2026012203191180900_bib7","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012203191180900_bib8","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"2026012203191180900_bib9","author":"Zolin","year":"2020"},{"key":"2026012203191180900_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026012203191180900_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"2026012203191180900_bib13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"2026012203191180900_bib15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib16","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis: what have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1378\/chest.14-1997","article-title":"The evolution of cystic fibrosis care","volume":"148","author":"Pittman","year":"2015","journal-title":"Chest"},{"key":"2026012203191180900_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1164\/rccm.201309-1659OC","article-title":"Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease","volume":"189","author":"Wielputz","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/thoraxjnl-2020-216085","article-title":"Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis","volume":"76","author":"Bayfield","year":"2021","journal-title":"Thorax"},{"key":"2026012203191180900_bib20","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012203191180900_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","article-title":"Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis","volume":"195","author":"Stahl","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib22","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ejrad.2011.02.045","article-title":"Morphologic and functional scoring of cystic fibrosis lung disease using MRI","volume":"81","author":"Eichinger","year":"2012","journal-title":"Eur J Radiol"},{"key":"2026012203191180900_bib23","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1002\/ppul.23537","article-title":"Early detection and sensitive monitoring of CF lung disease: prospects of improved and safer imaging","volume":"51","author":"Mall","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"2026012203191180900_bib24","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1002\/ppul.24931","article-title":"Novel imaging techniques for cystic fibrosis lung disease","volume":"56","author":"Goralski","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026012203191180900_bib25","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.chest.2020.12.008","article-title":"The clinical use of lung MRI in cystic fibrosis: what, now, how?","volume":"159","author":"Dournes","year":"2021","journal-title":"Chest"},{"key":"2026012203191180900_bib26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jcf.2020.11.019","article-title":"Sensitive structural and functional measurements and 1-year pulmonary outcomes in pediatric cystic fibrosis","volume":"20","author":"Willmering","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026012203191180900_bib27","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1513\/AnnalsATS.202208-684OC","article-title":"Effects of lumacaftor\/ivacaftor on cystic fibrosis disease progression in children 2 through 5 years of age homozygous for F508del-CFTR: a phase 2 placebo-controlled clinical trial","volume":"20","author":"Stahl","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203191180900_bib28","doi-asserted-by":"crossref","first-page":"00473-2022","DOI":"10.1183\/23120541.00473-2022","article-title":"Magnetic resonance imaging detects onset and association with lung disease severity of bronchial artery dilatation in cystic fibrosis","volume":"9","author":"Leutz-Schmidt","year":"2023","journal-title":"ERJ Open Res"},{"key":"2026012203191180900_bib29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jcf.2013.08.010","article-title":"Impact of different breathing protocols on multiple-breath washout outcomes in children","volume":"13","author":"Yammine","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2026012203191180900_bib30","doi-asserted-by":"crossref","first-page":"e230084","DOI":"10.1148\/radiol.230084","article-title":"Lung function in patients with cystic fibrosis before and during CFTR-modulator therapy using 3D ultrashort echo time MRI","volume":"308","author":"Heidenreich","year":"2023","journal-title":"Radiology"},{"key":"2026012203191180900_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17476348.2021.1908131","article-title":"A multimodal approach to detect and monitor early lung disease in cystic fibrosis","volume":"15","author":"Mondejar-Lopez","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2026012203191180900_bib32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.202102-0278OC","article-title":"Magnetic resonance imaging detects progression of lung disease and impact of newborn screening in preschool children with cystic fibrosis","volume":"204","author":"Stahl","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib34","doi-asserted-by":"crossref","first-page":"00408-2020","DOI":"10.1183\/23120541.00408-2020","article-title":"Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases","volume":"6","author":"Stahl","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026012203191180900_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.2007.077784","article-title":"Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis","volume":"63","author":"Gustafsson","year":"2008","journal-title":"Thorax"},{"key":"2026012203191180900_bib36","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.03.00049502","article-title":"Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis","volume":"22","author":"Gustafsson","year":"2003","journal-title":"Eur Respir J"},{"key":"2026012203191180900_bib37","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026012203191180900_bib38","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1053\/j.gastro.2004.07.006","article-title":"CFTR Cl-channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis","volume":"127","author":"Hirtz","year":"2004","journal-title":"Gastroenterology"},{"key":"2026012203191180900_bib39","first-page":"17","article-title":"Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates","volume":"4","author":"Paracchini","year":"2012","journal-title":"JIMD Rep"},{"key":"2026012203191180900_bib40","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012203191180900_bib41","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","article-title":"Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study","volume":"9","author":"Hoppe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012203191180900_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib43","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"21","author":"Wucherpfennig","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203191180900_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203191180900_bib45","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/11\/1550\/66014023\/annalsats_21_11_1550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/11\/1550\/66014023\/annalsats_21_11_1550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:19:23Z","timestamp":1769069963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/11\/1550\/8380752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202402-201oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"2024-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}